48 results about "Retinal progenitor" patented technology

Methods are provided for the in vitro differentiation of human retinal progenitor cells from embryonic stem cells.

This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.

The present invention relates to methods for culturing human retinal progenitor cells under low oxygen conditions to allow the cells to retain the ability to differentiate into photoreceptors following transplantation. The described methods provide cells that can treat a number of ocular diseases, including retinitis pigmentosa and age-related macular degeneration.

Disclosed herein are compositions and methods for treating, ameliorating or preventing a retinal disease or condition; improving a photopic (day light) vision; for improving correcting visual acuity, improving macular function, improving a visual field, or improving scotopic (night) vision by administration of retinal progenitor cells. The subject matter described herein also provides cell populations comprising retinal progenitor cells and methods of isolation thereof.

The invention relates to a method for inducing a human pluripotent stem cell to differentiate into an RPE cell. According to the method, an inhibitor is used for inducing the human pluripotent stem cell to differentiate into a neural precursor; after Shh, IGF1 and EGF growth factors are utilized to activate ERK 1/2, JNK, Sonic hedgehog signal routes, the cell is presented as the shape of neuroepithelium, Activen A and Chir99021 are added to activate TGFbeta and Wnt signal routes respectively to induce a neuro-epithelial cell into a retinal progenitor cell; adherent culture is conducted on theretinal progenitor cell to obtain an RPE cell at an underdeveloped state. The invention further studies the field of applying the underdeveloped RPE cell to treating retinal degenerative diseases. Compared with the prior art, the method firstly makes three stages of differentiating the human pluripotent stem cell to the underdeveloped RPE cell and related small molecular substances and growth factors used therein clear. Compared with a matured RPE, the underdeveloped RPE obtained through differentiation can treat the retinal degenerative diseases more effectively after being transplanted.

The invention belongs to the field of biomedicine, and specifically relates to a method used for inducing differentiation of human multipotential stem cells into retinal progenitor cells. According to the method, human embryonic stem cells or human induced multipotential stem cells are induced in a medium containing N2, and then are delivered into a retina induction medium containing neural basis culture medium, knockout serum replacement and nicotinamide so as to obtain the retinal progenitor cells. The method is capable of increasing differentiation rate of human multipotential stem cells into retinal progenitor cells; and the retinal progenitor cells obtained via differentiation can be used for transplantation therapy of irreversible degenerative diseases of retinal neurons, such as age-related macular degeneration and retinitis pigmentosa, and also can be used for iPS cells sourced from patients as cell models in drug screening and gene interference experiments. Compared with existing technology, small molecule compounds used in the method are less, so that influences caused by non-anthropogenic factors are avoided effectively, and yield of obtained optic cup-like cells is obviously higher than that of existing induced differentiation methods.

The invention discloses a method for preparing retinal progenitor cells derived from human pluripotent stem cells. The method comprises the following steps: selecting a 3d retinal cup which is subjected to induced differentiation for 50-60 days and derived from the human pluripotent stem cell, removing RPE and other non-3d retinal cup tissue, putting the retinal cup into a container with a liquidmedium, performing mechanical separation, separating and discarding a pigmentary layer of a dark and brown black part in the 3d retinal cup, retaining a nerve layer of a golden yellow part, further digesting the nerve layer into single cells, and putting the single cells into a culture plate which contains a RDM medium and is coated by Matrigel, so as to obtain the retinal progenitor cells. By adopting the method disclosed by the invention, 3d retinal tissue with stable quality can be obtained, retinal progenitor cells of which the number is controllable and the quality is controllable can beobtained, the time that the retinal progenitor cells are obtained can be shortened, obtaining procedures can be simplified, and the obtained retinal progenitor cells have good value increase performance and a capability of re-differentiated to other types of cells of retina.

The present invention pertains to a method for in vitro obtaining human retinal progenitors, comprising the steps of (i) placing an adherent culture of human pluripotent stem cells in a pro-neural medium; and (ii) maintaining this culture in said pro-neural medium until the appearance of pigmented cells and/or of neuroepithelial-like structures. Advantageously, additional steps can be perfonned to obtain RPE cells and/or precursors of the neural retina.

The present invention provides a method for maintaining a continuous epithelial structure of a retinal tissue including culturing the retinal tissue in a medium comprising a methyl group donor or a substrate of the methyl group donor at a concentration at which cell differentiation of a neural retinal progenitor cell is suppressed, and a neurite extension inhibitor at a concentration at which neurite extension is suppressed.

The present invention relates to substantially homogenous populations of human retinal progenitor cells having the following positive surface markers: SSEA4, CD73, PTK7 and PSA-NCAM. The invention also relates to method for preparing such substantially homogeneous cell populations from human tissue using cell sorting techniques.

The invention relates to an application of poly(sebacoyl diglyceride) in preparation of a retinal nerve cell carrier; retinal progenitor cells RPCs are proliferated, differentiated and migrated on the retinal nerve cell carrier, wherein a component of the retinal nerve cell carrier comprises poly(sebacoyl diglyceride) PSeD. The retinal nerve cell delivery carrier has the advantages of good biological compatibility, low cell inflammation expression, low cell apoptosis factor, and excellent neural differentiation promoting function.

The invention relates to the technical field of stem cells, and especially relates to a method and kit for identifying retinal progenitor cells capable of treating retinal degenerative change. The method comprises the following steps: culturing retinal progenitor cells to the logarithmic phase, and carrying out flow cytometry identification, wherein the retinal progenitor cells that meet the identification standards are capable of treating retinal degenerative change. The retinal progenitor cells identified by the provided method can maintain a good proliferation performance and stem cell characteristics and have a good curative effect when being applied to the treatment on retinal degenerative change. The experiment results show that after the retinal progenitor cells identified by the provided method are injected into the vitreous body cavities of RCS mice, the retinal outer nuclear layer cells are protected; the multifocal visual electrophysiology examination results show that the change of potential transmitted by retinal photoreceptor cells of the cell injection group is more prominent than the group, which is only injected with a HBSS buffer solution. The water maze experiment results also show that after injection, the visual performance of mice is improved.

The present invention provides a scaffold for culturing retinal tissue comprising an amount of gelatin, an amount of chondroitin sulfate, an amount of hyaluronic acid, wherein the amount of gelatin, chondroitin sulfate, and hyaluronic acid are prepared into a three-dimensional monolith, wherein the monolith is sectioned into planar sheets, and an amount of laminin-521.